The health ministry gave fast-track approval to the use of U.S. drugmaker Moderna Inc.’s COVID-19 vaccine doses as booster shots on Thursday, as Japan hopes to speed up the rollout of third doses amid worries over the highly transmissible omicron variant.
The move, which came a day after approval by a ministry panel, marked the second such approval after that for the Pfizer Inc.-BioNTech jab.
Japan began administering booster shots on Dec. 1, starting with health care workers. Moderna’s shot is set to be allocated to a workplace vaccination program starting around March. Studies have shown that, unlike Pfizer’s vaccine, a Moderna booster containing only half the dosage of each of the first two shots is needed to beef up immunity. It is also expected to have a low rate of side effects such as myocarditis, according to the U.K. Health Security Agency.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.